Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 16, 2025, titled "Closure of Remote Regulatory Assessment (RRA) by the USFDA at Matoda, Gujarat facility".
ZYDUSLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The USFDA carried out a Remote Regulatory Assessment (RRA) at Zydus Lifesciences' formulations manufacturing facility in Matoda, Gujarat. The assessment was for a Prior Approval Supplement (PAS) related to Atorvastatin Calcium Tablets in strengths of 10 mg, 20 mg, 40 mg, and 80 mg, used for cholesterol management. At the close of the assessment, the USFDA noted no observations (no Form 483 or deficiencies) and recommended the site for approval. This is a positive regulatory outcome for the company's US generics business. The filing was made under SEBI's Listing Obligations and Disclosure Requirements (Regulation 30).
Positive for shareholders — a clean USFDA closure with no observations and approval recommendation supports Zydus's ability to launch/supply Atorvastatin in the US market, strengthening its US revenue pipeline and reducing regulatory risk for this facility.